GEMCITABINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys Labs Ltd	GEMCITABINE HYDROCHLORIDE	gemcitabine hydrochloride	INJECTABLE;INJECTION	091365	ANDA	NorthStar Rx LLC	16714-909-01	1 VIAL, SINGLE-DOSE in 1 CARTON (16714-909-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2018-11-01
Dr Reddys Labs Ltd	GEMCITABINE HYDROCHLORIDE	gemcitabine hydrochloride	INJECTABLE;INJECTION	091365	ANDA	NorthStar Rx LLC	16714-930-01	1 VIAL, SINGLE-DOSE in 1 CARTON (16714-930-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2018-11-01
Dr Reddys Labs Ltd	GEMCITABINE HYDROCHLORIDE	gemcitabine hydrochloride	INJECTABLE;INJECTION	091365	ANDA	Dr. Reddy's Laboratories Limited	55111-686-07	1 VIAL, SINGLE-USE in 1 CARTON (55111-686-07) / 5 mL in 1 VIAL, SINGLE-USE	2011-07-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Gemcitabine hydrochloride is a nucleoside analog used primarily as an antineoplastic agent in the treatment of various cancers, including pancreatic, non-small cell lung, bladder, breast, and ovarian cancers. As a critical component in oncology therapeutics, the supply chain for gemcitabine hydrochloride is vital for pharmaceutical manufacturers, healthcare providers, and patients globally. This article examines the primary suppliers, manufacturing landscape, regulatory considerations, and market dynamics influencing the global availability of gemcitabine hydrochloride.

Overview of Gemcitabine Hydrochloride

Gemcitabine hydrochloride, chemically known as 4-amino-1-[(2R,3S)-3-hydroxy-2-(hydroxymethyl)propyl]-2(1H)pyrimidinone chloride, obstructs DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase. It is typically administered via intravenous infusion and supplied in various dosage forms and strengths, predominantly as lyophilized powders or pre-filled syringes.

The global demand for gemcitabine hydrochloride is driven by its pivotal role in cancer treatment protocols, with continued research and combination therapies expanding its usage. As a patented drug initially developed in the 1990s, generic manufacturing has since increased market accessibility, with multiple suppliers involved in production.

Major Suppliers and Manufacturers

1. Originating and Patent Holders

Eli Lilly and Company was the original developer of gemcitabine, obtaining patent protection in the 1990s. Since patent expiration, manufacturing rights have fragmented, leading to a proliferation of generic producers.

2. Leading Generics Manufacturers

Sun Pharmaceutical Industries Ltd.
As one of the world's largest generics manufacturers, Sun Pharma produces gemcitabine hydrochloride for multi-regional markets, including the United States, Europe, and India. Their robust manufacturing infrastructure ensures consistent supply and adherence to regulatory standards.
Cipla Limited
Headquartered in India, Cipla supplies gemcitabine hydrochloride to numerous emerging markets. Their offerings comply with international Good Manufacturing Practices (GMP), and their strategic positioning supports market penetration.
Dr. Reddy's Laboratories
Dr. Reddy's manufactures and markets gemcitabine hydrochloride globally, emphasizing quality and affordability. Their production facilities are GMP-certified, with approvals from the FDA, EMA, and other regulatory agencies.
Hospira (a Pfizer company)
Hospira has historically supplied gemcitabine as part of its oncology pipeline. Although acquisition by Pfizer has integrated its portfolio, Hospira’s manufacturing facilities remain integral in distribution.
Fresenius Kabi
Specializing in injectable medicines, Fresenius Kabi supplies gemcitabine hydrochloride as a sterile injectable, emphasizing high-quality standards and global distribution.
Luye Pharma Group
A significant Chinese pharmaceutical manufacturer, Luye Pharma produces gemcitabine for domestic and international markets, expanding the supply network in Asia.
Biocon Limited
An Indian biopharmaceutical firm, Biocon offers biosimilar versions of gemcitabine, contributing to the global supply chain, especially in developing countries.

3. Additional Regional Suppliers

In addition to these major players, several regional and local manufacturers in Asia, Eastern Europe, and Latin America produce gemcitabine hydrochloride to meet domestic and nearby international demand. These include companies like Sun Pharmaceutical Industries (India), Hangzhou Derun Pharmaceutical (China), and Tecnoquímicas (Colombia).

Manufacturing and Quality Control

Manufacturers of gemcitabine hydrochloride employ complex synthesis routes involving multiple chemical reactions, including purification steps to ensure high purity standards—often exceeding 99%. Regulatory compliance, particularly adherence to GMP guidelines set by agencies such as the US FDA, EMA, and Japan’s PMDA, is essential.

Supply chains are heavily scrutinized for contamination risks, stability, and consistent potency. Many suppliers have invested in advanced manufacturing technologies, including continuous manufacturing and in-line quality testing, to ensure reliability.

Supply Chain and Distribution Channels

Suppliers distribute gemcitabine hydrochloride to pharmaceutical companies, hospitals, and third-party logistics providers. Major distributors include pharmaceutical wholesalers and direct sales divisions of manufacturing firms. Geopolitical factors, trade regulations, and export restrictions influence regional availability.

The increasing adoption of biosimilars and generic versions has expanded supply options, decreasing prices and improving accessibility. However, supply disruptions may occur due to regulatory delays, manufacturing scale-up issues, or raw material shortages.

Regulatory Landscape

Regulatory approval is a critical hurdle. Suppliers must obtain approvals or acceptances of their manufacturing facilities and product registrations from agencies like the FDA (United States), EMA (Europe), and PMDA (Japan). Differences in regulatory standards can influence the supplier’s market access and competitive positioning.

Emerging markets often rely on local or regional approval pathways, creating variation in supplier legitimacy and product quality. Suppliers that maintain strict GMP compliance and possess WHO prequalification status are better positioned to ensure uninterrupted supply and market trust.

Market Dynamics Influencing Supplier Strategies

Patent Expiry and Generic Entry: The expiration of Eli Lilly’s patent opened markets for numerous generics, amplifying supply sources and reducing costs.
Manufacturing Capacity Expansion: Suppliers are investing in capacity expansion to meet rising demand, especially in Asia, where cancer prevalence increases.
Pricing and Market Competition: Competitive pricing drives suppliers to optimize production costs while maintaining quality, influencing the global supply landscape.
Supply Chain Resilience: The COVID-19 pandemic underscored the importance of supply chain robustness. Suppliers focus on diversifying manufacturing sites and stockpiling to mitigate disruptions.

Key Challenges for Suppliers

Ensuring product quality and batch consistency across diverse manufacturing sites.
Navigating complex regulatory approval processes internationally.
Managing raw material volatility, especially in fine chemicals.
Addressing environmental and safety standards, particularly in chemical synthesis.

Conclusion

The supply of gemcitabine hydrochloride hinges on a broad network of global manufacturers, primarily comprising Indian, Chinese, and Western generics firms. Major suppliers like Sun Pharma, Cipla, Dr. Reddy’s, and Fresenius Kabi dominate regional markets, with their manufacturing facilities complying with international regulatory standards. The evolving landscape, characterized by patent expirations, increased biosimilar competition, and heightened supply chain resilience efforts, continues to shape market dynamics. Ensuring consistent, high-quality supply remains paramount for healthcare systems worldwide, underpinning ongoing investments and strategic partnerships among manufacturers and distributors.

Key Takeaways

The global supply of gemcitabine hydrochloride is primarily driven by Indian and Chinese manufacturers offering cost-effective, GMP-compliant products.
Major suppliers include Sun Pharma, Cipla, Dr. Reddy’s, Fresenius Kabi, and regional producers, collectively meeting growing global demand.
Regulatory compliance and manufacturing quality are crucial in maintaining supply continuity and market trust.
Supply chain diversification and capacity expansion are strategic responses to recent market pressures and geopolitical factors.
Continued innovation and regulatory navigation are vital for market players to sustain and grow their share in the gemcitabine hydrochloride sector.

FAQs

1. Who are the primary global suppliers of gemcitabine hydrochloride?
Major suppliers include Indian firms like Sun Pharmaceutical Industries, Cipla, Dr. Reddy’s Laboratories, Chinese manufacturers like Luye Pharma, and multinational companies such as Fresenius Kabi, all offering GMP-compliant products.

2. What factors influence the pricing of gemcitabine hydrochloride?
Pricing is impacted by manufacturing costs, raw material availability, regulatory compliance expenses, market competition, and regional demand-supply dynamics.

3. Are there regional differences in approved suppliers for gemcitabine?
Yes. Regulatory agencies’ specific approval processes influence which suppliers can distribute in certain regions, with North America and Europe generally requiring stringent GMP and registration.

4. How has patent expiration affected the supply landscape?
Patent expiration has facilitated entry by multiple generic producers, increasing supply options, reducing prices, and expanding access in emerging markets.

5. What challenges do suppliers face in maintaining supply continuity?
Key challenges include raw material shortages, regulatory delays, manufacturing scaling issues, ensuring consistent quality, and geopolitical trade restrictions.

Sources:
[1] Market data from pharmaceutical industry reports and FDA approvals (2022-2023).
[2] Company disclosures and regulatory filings for manufacturing and approval status.
[3] Industry analyses on generic drug manufacturing and global oncology drug markets.

Suppliers and packagers for generic pharmaceutical drug: GEMCITABINE HYDROCHLORIDE